Marijuana use -- by either men or women -- does not lower a couple's chances of becoming parent, finds a study challenging previous theories.
While marijuana is one of the most widely used recreational drugs among individuals of reproductive age, it has also long been promoted as an effective treatment for a range of medical conditions, including epilepsy and chronic pain.
Previous studies have also shown that marijuana use has adverse effects on male fertility as it lowers sperm count and quality, and smoking the weed impacts both egg quality and a woman's menstrual cycle.
The new study, published in the Journal of Epidemiology and Community Health, demonstrated that there was no link between fecundability -- the average per-cycle probability of conception -- and marijuana use.
Marijuana has been legalised for recreational purposes in nine states of the US.
"Given the increasing number of states legalising recreational marijuana across the nation, we thought it was an opportune time to investigate the association between marijuana use and fertility," said lead author Lauren Wise, Professor at the Boston University School of Public Health (BUSPH).
While animal studies have indicated that the risk for miscarriage increases if marijuana is used early in pregnancy, some associations have been found between marijuana use during pregnancy and future developmental and hyperactivity disorders in children.
For the study, the team had surveyed 4,194 women aged 21 to 45 living in the US or Canada from 2013 through 2017.
After 12 cycles of follow-up, conception probabilities were found to be similar among couples that used marijuana and those that did not.
However, the questions about the effects of marijuana use still remain, as classifying people correctly according to the amount of marijuana used, especially when relying on self-reported data, is challenging, the researchers said.
"Future studies with day-specific data on marijuana use might better be able to distinguish acute from chronic effects of marijuana use, and evaluate whether effects depend on other factors," Wise said.
--IANS
rt/in/bg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
